logo-loader
Acasti Pharma Inc

Full interview: Acasti Pharma receives $750,000 grant from National Research Council of Canada

Acasti Pharma (CVE: ACST) Co-founder COO and Chief Scientific Officer Dr, Pierre Lemieux joined Steve Darling from Proactive Vancouver on Skype to discuss the company has received a sizable grant from the Canadian Government to help their drug development work.

Lemieux telling Proactive what the money will be used for and also an update on the development of CaPre. 

Quick facts: Acasti Pharma Inc

Price: $2.80

Market: TSX-V
Market Cap: $237.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Acasti Pharma gets new Chinese patent that paves the way for its heart...

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) Co-Founder and COO Pierre Lemieux tells Proactive Investors it was awarded a second patent in China covering its flagship drug candidate CaPre, an omega-3 phospholipid. Lemieux says currently in China there is no approved drug like CaPre, where...

on 06/26/2019

2 min read